Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure

Recruiting

• Conditions: Heart Failure; Pulmonary Hypertension; Pulmonary Vascular Resistance Abnormality

• Registration Number: NCT06331208
• Lead Sponsor: Institute for Clinical and Experimental Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-2-23
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

A) Inclusion Criteria<br><br>HF group:<br><br> - age>18y<br><br> - signed informed consent,<br><br> - left ventricular (LV) ejection fraction <50%<br><br> - duration of HF>6 months,<br><br> - loop diuretic use,<br><br> - clinical indication to right heart catheterisation<br><br>Control group:<br><br> - Age >18years<br><br> - Signed informed consent<br><br> - Non-HF subjects referred to Institute for Clinical and Experimental Medicine (IKEM)<br> in Prague for an invasive procedure (PFO closure, arrhythmia ablation, for subjects<br> undergoing RHC) or non-invasive diagnostic evaluation (controls without invasive<br> sampling)<br><br>B) Exclusion Criteria:<br><br>Heart Failure group:<br><br> - Patients with hemodynamic instability requiring inotropic support<br><br> - Severe renal insufficiency (estimated glomerular filtration rate <0.6 ml/s)<br><br> - Acute coronary syndrome<br><br> - High cardiac output (cardiac index >4 l/m2)<br><br> - Known pulmonary hypertension of other type than II (type I, III, IV)<br><br> - Active infection<br><br> - Respiration insufficiency<br><br> - Large pleural effusion<br><br> - Severe intrinsic lung disease (treated chronic obstructive pulmonary disease (COPD)<br><br> - asthma, known interstitial lung disease)<br><br>Control group:<br><br> - Pulmonary hypertension (RV systolic pressure estimate on screening > 45 mmHg)<br><br> - History of recent pulmonary embolism < 1 year<br><br> - Echocardiographic evidence of reduced function of right or left ventricle<br><br> - Treated asthma/COPD, known intersticial lung disease<br><br> - Significant exercise intolerance (NYHA > II)

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
biomarker of pulmonary vasculopathy in HF;CT characteristics of pulmonary vasculopathy in HF;CT characteristics of presence of heart failure